JP2024534991A5 - - Google Patents

Info

Publication number
JP2024534991A5
JP2024534991A5 JP2024515645A JP2024515645A JP2024534991A5 JP 2024534991 A5 JP2024534991 A5 JP 2024534991A5 JP 2024515645 A JP2024515645 A JP 2024515645A JP 2024515645 A JP2024515645 A JP 2024515645A JP 2024534991 A5 JP2024534991 A5 JP 2024534991A5
Authority
JP
Japan
Prior art keywords
polynucleotide
sequence
nucleotides
seq
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/075185 external-priority patent/WO2023036966A1/en
Publication of JP2024534991A publication Critical patent/JP2024534991A/ja
Publication of JP2024534991A5 publication Critical patent/JP2024534991A5/ja
Pending legal-status Critical Current

Links

JP2024515645A 2021-09-10 2022-09-09 オトフェリンのアイソフォーム5をコードする二重組換えaav8ベクター系およびその使用 Pending JP2024534991A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21306245.8 2021-09-10
EP21306245 2021-09-10
US202263303743P 2022-01-27 2022-01-27
US63/303,743 2022-01-27
PCT/EP2022/075185 WO2023036966A1 (en) 2021-09-10 2022-09-09 Dual recombinant aav8 vector system encoding isoform 5 of otoferlin and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534991A JP2024534991A (ja) 2024-09-26
JP2024534991A5 true JP2024534991A5 (cg-RX-API-DMAC7.html) 2025-08-05

Family

ID=83598432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515645A Pending JP2024534991A (ja) 2021-09-10 2022-09-09 オトフェリンのアイソフォーム5をコードする二重組換えaav8ベクター系およびその使用

Country Status (9)

Country Link
US (1) US20250295716A1 (cg-RX-API-DMAC7.html)
EP (1) EP4398943A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024534991A (cg-RX-API-DMAC7.html)
KR (1) KR20240053630A (cg-RX-API-DMAC7.html)
AU (1) AU2022344528A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231374A1 (cg-RX-API-DMAC7.html)
IL (1) IL311345A (cg-RX-API-DMAC7.html)
MX (1) MX2024003052A (cg-RX-API-DMAC7.html)
WO (1) WO2023036966A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
CN116925239B (zh) * 2023-07-17 2024-10-18 苏州星奥拓维生物技术有限公司 双载体系统表达Otof基因的组合物和方法
CN117305367A (zh) * 2023-08-21 2023-12-29 复旦大学附属眼耳鼻喉科医院 一种表达全长耳畸蛋白的双aav载体系统及其应用
AU2024397647A1 (en) * 2023-12-11 2026-06-25 Akouos, Inc. Compositions and methods for treating hearing loss in a human subject having a defective otoferlin gene

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209226A1 (en) 2002-01-11 2003-07-30 Michael Tennant Adiponectin gene therapy
AU2003251931B2 (en) * 2002-07-17 2008-03-06 Bristol-Myers Squibb Company Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements
WO2006036465A2 (en) 2004-09-03 2006-04-06 University Of Florida Compositions and methods for treating cystic fibrosis
US7517870B2 (en) * 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
WO2011075838A1 (en) 2009-12-21 2011-06-30 Audigen Inc. Method of treating or preventing hearing loss
WO2013075008A1 (en) 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy
US10751385B2 (en) * 2015-02-20 2020-08-25 Institut Pasteur Prevention and/or treatment of hearing loss or impairment
IL325122A (en) * 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
WO2020093018A1 (en) * 2018-11-01 2020-05-07 University Of Florida Research Foundation, Incorporated A codon optimized otoferlin aav dual vector gene therapy
CN113924109A (zh) * 2019-01-18 2022-01-11 巴斯德研究所 Aav介导的基因疗法恢复耳畸蛋白基因
EP3921032A4 (en) * 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
TWI896570B (zh) * 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
KR20240004253A (ko) * 2021-02-19 2024-01-11 데시벨 테라퓨틱스, 인크. 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 방법

Similar Documents

Publication Publication Date Title
JP2022522996A5 (cg-RX-API-DMAC7.html)
JP2023070682A5 (cg-RX-API-DMAC7.html)
JP2025063057A5 (cg-RX-API-DMAC7.html)
FI3911354T3 (fi) Otoferliinigeenin palauttava AAV-välitteinen geeniterapia
JP2023503637A5 (cg-RX-API-DMAC7.html)
JP2022500066A5 (cg-RX-API-DMAC7.html)
JP2021513863A5 (cg-RX-API-DMAC7.html)
US20050169892A1 (en) Adeno-associated virus materials and methods
KR20220093163A (ko) 안구 유전자 전달을 위한 aav 벡터 변이체
JP2020518259A5 (cg-RX-API-DMAC7.html)
JP7654562B2 (ja) 線維芽細胞増殖因子23関連低リン血症性疾患の遺伝子療法
JP2022513308A5 (cg-RX-API-DMAC7.html)
JP2021500922A5 (cg-RX-API-DMAC7.html)
JP2024507837A5 (cg-RX-API-DMAC7.html)
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP2021530227A5 (cg-RX-API-DMAC7.html)
JP2019524090A5 (cg-RX-API-DMAC7.html)
JP2020503265A5 (cg-RX-API-DMAC7.html)
JP2025521102A5 (cg-RX-API-DMAC7.html)
CN117242183A (zh) 用于治疗与血管生成相关的眼部疾病的组合物和方法
CN115885040A (zh) 可用于治疗cdkl5缺乏症(cdd)的组合物
JP2021512871A5 (cg-RX-API-DMAC7.html)
JP2022529500A5 (cg-RX-API-DMAC7.html)
JP2023544633A5 (cg-RX-API-DMAC7.html)
O'Neill et al. Comparison of SNCG and NEFH promoter–driven expression of human SIRT1 expression in a mouse model of glaucoma